An interventional study of MR imaging and Glucose clamp in Diabetes Mellitus, sponsored by Pfizer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-07.
Sponsored by Pfizer · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Diabetes Mellitus by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus · Pfizer.
Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 23rd largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is the only one with no phase, and was the 10th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 35 studies in Diabetes Mellitus by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 13 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 182 across the 30 interventional studies, 3,720 across the 2 observational. Of the 30 that completed or were terminated, 15 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Diabetes Mellitus by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assess pancreatic beta cell function using MR imaging.
The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Also known as: R-Gene 10
Pancreatic perfusion
The record gives a start of Dec 2005 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine